Protecting IP and Addressing Business Concerns
Establishing and Managing Life Sciences Companies
Increased pricing pressure combined with a rise in generic competition and continued regulatory uncertainty have squeezed the margins of life sciences companies. Now, more than ever, they need someone who understands their industry, knows the players, and can help navigate the ever-shifting terrain. Saul Ewing’s Life Sciences Practice consists of approximately 40 professionals, the majority of whom have direct industry experience – including as scientists, engineers, entrepreneurs and investors. We are business people first. As a result, we are able to give legal advice that is practical and business-oriented to guide companies in pursuing their business goals. This advice includes the development of a comprehensive intellectual property strategy that mirrors strategic plans for product development and regulatory approval, as well as providing wide-ranging corporate advice for the establishment and management of companies through iterative rounds of financing, partnering and eventual exit.
Protecting Life Sciences Companies' Intellectual Property
Protecting intellectual property (IP) is paramount to the success of life sciences entities. Our attorneys understand the risks they face when their IP and brand are threatened, and we have deep experience helping clients protect them when disputes escalate into litigation. Our IP Litigation team includes attorneys who serve as New Jersey litigation counsel in patent cases for more than two dozen pharmaceutical and medical device companies. They have secured major trial victories in ANDA (Abbreviated New Drug Application) cases where hundreds of millions of dollars in sales were at stake. Saul Ewing was ranked fourth, nationally, for the number of cases filed on behalf of patentees (2015-2017), and on behalf of ANDA plaintiffs (2009-2017). We also advocate for clients at emergent proceedings for restraining orders and injunctions and enforce and defend IP rights pursuant to confidentiality agreements.